TargetBeta
S1PR1
sphingosine-1-phosphate receptor 1 · also edg-1, D1S3362, CD363, EDG1 · Sphingosine 1-phosphate receptors
5 programs in company-led studies act on S1PR1, from 4 companies: 4 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| fingolimodrule | Novartis | phase 4 | 554 running | S1PR2, S1PR3, S1PR4, S1PR5 | NCIt |
| cenerimodrule | Viatris | phase 3 | 145 running | – | ChEMBL |
| etrasimodrule | Pfizer | phase 3 | 214 running | S1PR4, S1PR5 | ChEMBL |
| ponesimodrule | Johnson & Johnson | phase 3 | 162 running | – | NCIt |
| mocravimodrule | Novartis | phase 3 | 51 running | MBTPS1 | ChEMBL |
Conditions their studies are in
- Colitis, Ulcerative, 3 programs
- Multiple Sclerosis, 2 programs
- Renal Insufficiency, 2 programs
- Alopecia Areata, 1 program
- Bronchiolitis Obliterans Syndrome, 1 program
- Crohn Disease, 1 program
- Dermatitis, Atopic, 1 program
- Eosinophilic Esophagitis, 1 program
- Hematologic Neoplasms, 1 program
- Leukemia, Myeloid, Acute, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 31, 2026cenerimod · Viatris · phase 3 · NCT05672576
- May 2027mocravimod · Novartis · phase 3 · NCT05429632
- Aug 2028ponesimod · Johnson & Johnson · phase 3 · NCT07362017
- Jun 16, 2029etrasimod · Pfizer · phase 3 · NCT05287126
- Jan 1, 2030fingolimod · Novartis · phase 4 · NCT07220252
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.